Ranbaxy: Better than its global peers? - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

Ranbaxy: Better than its global peers?

Apr 5, 2006

The past one year has been a testing time for Ranbaxy due to intense competition and price erosion faced in its key market, the US. Its global peers such as Teva, Mylan and Watson have not been spared either. Since Ranbaxy is competing in the global generics space, in this article, we have analysed its performance vis--vis its international peers.

A look at the financials
(US$ m) (CY05/FY05) Teva Mylan* Watson Ranbaxy
Net sales 5,250 1,253 1,646 1,180
Net sales (3 year CAGR) 27.7% 4.3% 10.4% 11.5%
EBIDTA 1,522 347 425 86
EBIDTA margin (%) 29.0% 27.7% 25.8% 7.3%
Net profit 1,081 204 138 56
Net profit margin (%) 20.6% 16.2% 8.4% 4.8%
Net profit (3 year CAGR) 37.9% -7.9% -7.7% -26.9%
R&D expenditure 7.0% 7.0% 7.6% 8.8%
SG&A expenses 15.2% 20.7% 15.9% 25.5%

To Read the Full Story, Subscribe or Sign In
To Read the Full Story, Subscribe or Sign In

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms


Apr 1, 2015 (Close)


  • Track your investment in RANBAXY LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks